αααααβααΎαIOVA β’ NASDAQ
add
Iovance Biotherapeutics Inc
2.73$
αααααααααα(1.10%)+0.030
2.76$
ααΆααα·αα 31 ααααΌ, 7:35:48 PM ααααβααα -5 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·αααΆαααΈααααΆααααΆααααααΆααα
α’αΆαααα·α
αα·αααΈαα»α
2.77$
α
αααααααααααα
2.69$ - 2.83$
α
ααααααα½αααααΆαα
α»αααααα
1.64$ - 8.15$
ααΎαβαα»αβααΈααααΆα
1.08Β αααΈααΆα USD
ααα ααα½αααΌαααααα
11.13Β ααΆα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
NASDAQ
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 67.46Β ααΆα | 15.20% |
α
αααΆαααααα·ααααα·ααΆα | 118.74Β ααΆα | 2.27% |
α
αααΌααα»ααα | -91.25Β ααΆα | -9.23% |
ααααΆααα
αααααα»ααα | -135.28 | 5.18% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -0.25 | 10.71% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -81.00Β ααΆα | 0.62% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 2.57% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 300.80Β ααΆα | -24.32% |
ααααααααα»α | 904.95Β ααΆα | -8.69% |
ααΆαααα½ααα»αααααΌαααα»α | 202.66Β ααΆα | -6.89% |
ααΌαβααααα»α | 702.29Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 396.97Β ααΆα | β |
ααααααααααΉαααααα
| 1.52 | β |
ααα
ααααααΎαααααα | -24.76% | β |
ααα
ααααααΎααΎααα»α | -29.79% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -91.25Β ααΆα | -9.23% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -78.70Β ααΆα | -33.45% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | 17.01Β ααΆα | 134.86% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 88.06Β ααΆα | 109.89% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 25.69Β ααΆα | 139.78% |
ααα αΌαααΆα
αααααΆααααααα | -52.92Β ααΆα | -121.55% |
α’αααΈ
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer. Wikipedia
ααΆααααααΎαα‘αΎα
2007
ααΆαα·ααΆαααβαααααΆα
αααααβαααααΆα
αα»ααααα·α
838